\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\:\\ \\ temp\\ 36\\.4\\,\\ hr\\ 64\\,\\ bp\\ 103\\/55\\,\\ rr\\ 18\ \(0\)\
\-\ there\\ was\\ marked\\ proptosis\\ and\\ lagophthalmos\\ bilaterally\\ with\\ injection\\ of\\ the\\ sclera\\ and\\ conjunctiva\\ of\\ the\\ right\\ eye\\.\\ \\ left\\ lid\\ was\\ ptotic\\.\\ heart\\ exam\\ revealed\\ a\\ regular\\ rate\\ and\\ rhythm\\.\\ \\ there\\ was\\ 2\\+\\ pitting\\ edema\\ of\\ the\\ lower\\ extremities\\ bilaterally\\.\ \(0\)\
\-\ the\\ patient\\ was\\ taken\\ to\\ surgery\\ based\\ on\\ outside\\ imaging\\ studies\\ that\\ were\\ not\\ reviewed\\ by\\ our\\ institution\\â\\€\\™s\\ radiologists\\.\\ \\ the\\ surgery\\ failed\\ to\\ improve\\ the\\ patient\\â\\€\\™s\\ ocular\\ symptoms\\,\\ and\\ three\\ weeks\\ later\\ the\\ patient\\ underwent\\ imaging\\ studies\\ at\\ our\\ institution\\,\\ which\\ are\\ displayed\\ in\\ this\\ case\\.\\ \\ \ \(0\)\
\-\ when\\ the\\ imaging\\ findings\\ reviewed\\ by\\ the\\ neuroradiologists\\ strongly\\ suggested\\ metastatic\\ disease\\ greater\\ than\\ thyroid\\ disease\\,\\ the\\ patient\\ was\\ taken\\ back\\ to\\ the\\ operating\\ room\\ and\\ a\\ biopsy\\ of\\ his\\ right\\ lateral\\ rectus\\ muscle\\ was\\ obtained\\.\\ \\ \ \(0\)\
\-\ pathology\\ confirmed\\ poorly\\ differentiated\\ prostate\\ adenocarcinoma\\.\\ \\ \ \(0\)\
\-\ the\\ patient\\ was\\ offered\\ radiation\\ therapy\\ to\\ the\\ orbits\\ but\\ he\\ declined\\.\\ \\ approximately\\ 6\\ months\\ later\\ he\\ suffered\\ total\\ vision\\ loss\\ bilaterally\\.\ \(0\)\
\-\ \\Â\\»\\ ct\\:\\ severe\\ bilateral\\ exophthalmos\\ is\\ noted\\.\\ \\ there\\ is\\ enlargement\\ of\\ the\\ medial\\ rectus\\ muscles\\ bilaterally\\,\\ the\\ right\\ lateral\\ rectus\\,\\ and\\ the\\ left\\ superior\\ rectus\\.\\ \\ the\\ lamina\\ papyracea\\ is\\ disrupted\\ bilaterally\\ with\\ herniation\\ of\\ the\\ medial\\ rectus\\ muscles\\.\\ \\ the\\ optic\\ nerves\\ are\\ compressed\\ bilaterally\\ by\\ the\\ extraocular\\ muscles\\.\ \(0\)\
\-\ \\Â\\»\\ mr\\:\\ again\\ seen\\ is\\ the\\ enlargement\\ of\\ the\\ bilateral\\ medial\\ rectus\\ muscles\\,\\ left\\ superior\\ rectus\\,\\ and\\ right\\ lateral\\ rectus\\.\\ \\ the\\ inferior\\ rectus\\ muscles\\ are\\ spared\\ bilaterally\\.\\ \\ the\\ enlarged\\ muscles\\ demonstrate\\ both\\ enhancement\\ and\\ restricted\\ diffusion\\.\\ \\ the\\ optic\\ nerves\\ are\\ compressed\\ bilaterally\\.\ \(0\)\
\-\ prostate\\ cancer\\ metastases\\,\\ orbit\\,\\ extraocular\\ muscles\ \(0\)\
\-\ \\â\\€\\¢\\ thyroid\\-associated\\ orbitopathy\ \(0\)\
\-\ \\â\\€\\¢\\ metastases\\ to\\ eoms\ \(0\)\
\-\ \\â\\€\\¢\\ idiopathic\\ orbital\\ pseudotumor\ \(0\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ an\\ 84\\ year\\-old\\ man\\ presented\\ with\\ several\\ weeks\\ of\\ decreased\\ vision\\,\\ diplopia\\,\\ and\\ proptosis\\.\\ \\ review\\ of\\ systems\\ was\\ unremarkable\\.\\ \\ his\\ past\\ medical\\ history\\ was\\ significant\\ for\\ prostate\\ cancer\\ status\\ post\\ xrt\\ for\\ bone\\ metastases\\.\\ \\ the\\ patient\\ underwent\\ bilateral\\ orbital\\ decompression\\ surgery\\ for\\ his\\ ocular\\ symptoms\\ based\\ on\\ outside\\ images\\ not\\ reviewed\\ at\\ our\\ institution\\.\ \(0\)\
\-\ this\\ case\\ illustrates\\ the\\ importance\\ of\\ assessing\\ the\\ pattern\\ of\\ extraocular\\ muscle\\ involvement\\.\\ \\ the\\ patient\\â\\€\\™s\\ presentation\\ is\\ suggestive\\ of\\ thyroid\\-associated\\ orbitopathy\\.\\ \\ however\\,\\ the\\ imaging\\ does\\ not\\ support\\ this\\ diagnosis\\.\\ \\ the\\ inferior\\ rectus\\ muscles\\ are\\ spared\\,\\ as\\ is\\ the\\ left\\ lateral\\ rectus\\ muscle\\.\\ \\ thyroid\\-associated\\ orbitopathy\\ is\\ typically\\ characterized\\ by\\ bilateral\\ and\\ more\\ symmetric\\ muscle\\ involvement\\.\\ \\ the\\ inferior\\ muscle\\ group\\ is\\ involved\\ most\\ commonly\\,\\ followed\\ by\\ \\(in\\ decreasing\\ order\\ of\\ frequency\\)\\ medial\\,\\ superior\\,\\ and\\ lateral\\ rectus\\ muscles\\.\\ \\ additionally\\,\\ the\\ muscle\\ tendons\\ are\\ usually\\ spared\\ \\-\\ in\\ distinction\\ from\\ orbital\\ pseudotumor\\ and\\ lymphoma\\.\ \(0\)\
\-\ metastases\\ to\\ the\\ extraocular\\ muscles\\ are\\ a\\ rare\\ occurrence\\,\\ comprising\\ only\\ 9\\%\\ of\\ all\\ cases\\ of\\ orbital\\ metastases\\.\\ \\ the\\ most\\ common\\ primary\\ malignancies\\ are\\ breast\\ and\\ cutaneous\\ melanoma\\.\\ \\ one\\ study\\ reports\\ the\\ order\\ of\\ most\\ commonly\\ involved\\ muscles\\,\\ in\\ decreasing\\ frequency\\,\\ as\\ medial\\ \\(39\\%\\)\\,\\ lateral\\ \\(33\\%\\)\\,\\ superior\\ \\(16\\%\\)\\,\\ and\\ inferior\\ \\(12\\%\\)\\.\\ \\ cases\\ of\\ unilateral\\,\\ asymmetric\\ extraocular\\ muscle\\ disease\\ far\\ outnumbered\\ those\\ of\\ bilateral\\,\\ symmetric\\ disease\\ as\\ seen\\ in\\ thyroid\\-associated\\ orbitopathy\\.\ \(0\)\
\-\ references\\:\\ \ \(0\)\
\-\ lacey\\ b\\,\\ chang\\ w\\,\\ rootman\\ j\\.\\ \\ nonthyroid\\ causes\\ of\\ extraocular\\ muscle\\ disease\\.\\ \\ surv\\ ophthalmol\\ 1999\\;\\ 44\\:187\\â\\€\\“213\\.\ \(0\)\
\-\ goldberg\\ ra\\,\\ rootman\\ j\\,\\ cline\\ ra\\.\\ \\ tumors\\ metastatic\\ to\\ the\\ orbit\\:\\ a\\ changing\\ picture\\.\\ surv\\ ophthalmol\\ 1990\\;\\ 35\\:1\\-24\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ rectus\\:\\ 0\\.412010975941827\ \(0\)\
\-\ muscles\\:\\ 0\\.312728873205931\ \(0\)\
\-\ the\\:\\ 0\\.2515474855812141\ \(0\)\
\-\ extraocular\\:\\ 0\\.2165124398578826\ \(0\)\
\-\ muscle\\:\\ 0\\.18845315495931747\ \(0\)\
\-\ orbitopathy\\:\\ 0\\.1830748504699598\ \(0\)\
\-\ bilaterally\\:\\ 0\\.17700417581769953\ \(0\)\
\-\ metastases\\:\\ 0\\.13410182565510215\ \(0\)\
\-\ thyroid\\:\\ 0\\.1303590241676154\ \(0\)\
\-\ of\\:\\ 0\\.1233528577094529\ \(0\)\
\-\ spared\\:\\ 0\\.1181383012131999\ \(0\)\
\-\ orbital\\:\\ 0\\.11639645832411845\ \(0\)\
\-\ reviewed\\:\\ 0\\.11509630243276928\ \(0\)\
\-\ medial\\:\\ 0\\.10797295933707693\ \(0\)\
\-\ surv\\:\\ 0\\.10610899349160764\ \(0\)\
\-\ was\\:\\ 0\\.10405722520115124\ \(0\)\
\-\ are\\:\\ 0\\.10070808297275566\ \(0\)\
\-\ lateral\\:\\ 0\\.09878498059799844\ \(0\)\
\-\ institution\\:\\ 0\\.09842519154665061\ \(0\)\
\-\ rootman\\:\\ 0\\.09804662119339928\ \(0\)\
\-\ prostate\\:\\ 0\\.09640004360329797\ \(0\)\
\-\ and\\:\\ 0\\.09597371943853544\ \(0\)\
\-\ ophthalmol\\:\\ 0\\.09545111703916444\ \(0\)\
\-\ inferior\\:\\ 0\\.09027875931646333\ \(0\)\
\-\ bilateral\\:\\ 0\\.08914810129613636\ \(0\)\
\-\ our\\:\\ 0\\.08816989139408811\ \(0\)\
\-\ superior\\:\\ 0\\.08627451422099733\ \(0\)\
\-\ patient\\:\\ 0\\.07553177451697604\ \(0\)\
\-\ decreasing\\:\\ 0\\.07461018698144278\ \(0\)\
\-\ is\\:\\ 0\\.0726822089610712\ \(0\)\
\-\ compressed\\:\\ 0\\.07186062038242297\ \(0\)\
\-\ by\\:\\ 0\\.0704407421578265\ \(0\)\
\-\ imaging\\:\\ 0\\.0697389317668267\ \(0\)\
\-\ disease\\:\\ 0\\.0696290222073035\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.06890348468014379\ \(0\)\
\-\ ocular\\:\\ 0\\.06799073859060464\ \(0\)\
\-\ proptosis\\:\\ 0\\.06694214209126845\ \(0\)\
\-\ ra\\:\\ 0\\.06561679436443375\ \(0\)\
\-\ frequency\\:\\ 0\\.06305713475176283\ \(0\)\
\-\ nerves\\:\\ 0\\.06196159196541076\ \(0\)\
\-\ orbit\\:\\ 0\\.06145023293755352\ \(0\)\
\-\ order\\:\\ 0\\.061325830205904895\ \(0\)\
\-\ his\\:\\ 0\\.06036002472230892\ \(0\)\
\-\ to\\:\\ 0\\.05805628574738881\ \(0\)\
\-\ vision\\:\\ 0\\.05746529102063899\ \(0\)\
\-\ optic\\:\\ 0\\.05711544376062456\ \(0\)\
\-\ symmetric\\:\\ 0\\.056859795128351084\ \(0\)\
\-\ surgery\\:\\ 0\\.05350930286179962\ \(0\)\
\-\ outside\\:\\ 0\\.05326345790769654\ \(0\)\
\-\ involved\\:\\ 0\\.05320175195644002\ \(0\)\
\-\ lagophthalmos\\:\\ 0\\.05305449674580382\ \(0\)\
\-\ neuroradiologists\\:\\ 0\\.05305449674580382\ \(0\)\
\-\ outnumbered\\:\\ 0\\.05305449674580382\ \(0\)\
\-\ lacey\\:\\ 0\\.05305449674580382\ \(0\)\
\-\ nonthyroid\\:\\ 0\\.05305449674580382\ \(0\)\
\-\ cline\\:\\ 0\\.05305449674580382\ \(0\)\
\-\ taken\\:\\ 0\\.053018574241052566\ \(0\)\
\-\ most\\:\\ 0\\.05179626262611251\ \(0\)\
\-\ enlargement\\:\\ 0\\.05086764182581916\ \(0\)\
\-\ ptotic\\:\\ 0\\.05069640401515136\ \(0\)\
\-\ commonly\\:\\ 0\\.04909623123190811\ \(0\)\
\-\ studies\\:\\ 0\\.048671675178040226\ \(0\)\
\-\ based\\:\\ 0\\.048062554622422135\ \(0\)\
\-\ involvement\\:\\ 0\\.048023058677741585\ \(0\)\
\-\ chang\\:\\ 0\\.04772555851958222\ \(0\)\
\-\ goldberg\\:\\ 0\\.04772555851958222\ \(0\)\
\-\ later\\:\\ 0\\.04748375140798516\ \(0\)\
\-\ eoms\\:\\ 0\\.04666521786604718\ \(0\)\
\-\ papyracea\\:\\ 0\\.04576871261748995\ \(0\)\
\-\ underwent\\:\\ 0\\.04570688462551278\ \(0\)\
\-\ left\\:\\ 0\\.045267247733938594\ \(0\)\
\-\ cases\\:\\ 0\\.04462768976108221\ \(0\)\
\-\ cancer\\:\\ 0\\.04419416587271258\ \(0\)\
\-\ right\\:\\ 0\\.04399591334803877\ \(0\)\
\-\ pitting\\:\\ 0\\.04369437237047804\ \(0\)\
\-\ comprising\\:\\ 0\\.04314007007008428\ \(0\)\
\-\ conjunctiva\\:\\ 0\\.042634031716943\ \(0\)\
\-\ distinction\\:\\ 0\\.042168521557542665\ \(0\)\
\-\ exophthalmos\\:\\ 0\\.04173752646838577\ \(0\)\
\-\ in\\:\\ 0\\.04126466630655633\ \(0\)\
\-\ lid\\:\\ 0\\.04096093829849129\ \(0\)\
\-\ lamina\\:\\ 0\\.04096093829849129\ \(0\)\
\-\ changing\\:\\ 0\\.04096093829849129\ \(0\)\
\-\ as\\:\\ 0\\.03998306345388142\ \(0\)\
\-\ weeks\\:\\ 0\\.039765193634374495\ \(0\)\
\-\ sclera\\:\\ 0\\.03966318622137386\ \(0\)\
\-\ radiologists\\:\\ 0\\.03966318622137386\ \(0\)\
\-\ declined\\:\\ 0\\.03966318622137386\ \(0\)\
\-\ there\\:\\ 0\\.03960102416397746\ \(0\)\
\-\ lymphoma\\:\\ 0\\.03951586821211401\ \(0\)\
\-\ offered\\:\\ 0\\.0393794337377333\ \(0\)\
\-\ assessing\\:\\ 0\\.0393794337377333\ \(0\)\
\-\ not\\:\\ 0\\.03929043545380465\ \(0\)\
\-\ he\\:\\ 0\\.039290370787209705\ \(0\)\
\-\ displayed\\:\\ 0\\.0391088839209801\ \(0\)\
\-\ disrupted\\:\\ 0\\.03885036259303637\ \(0\)\
\-\ xrt\\:\\ 0\\.038137335408438486\ \(0\)\
\-\ occurrence\\:\\ 0\\.038137335408438486\ \(0\)\
\-\ 1990\\:\\ 0\\.038137335408438486\ \(0\)\
\-\ orbits\\:\\ 0\\.0375022571947384\ \(0\)\
\-\ malignancies\\:\\ 0\\.03730509349072139\ \(0\)\
\-\ operating\\:\\ 0\\.03692975214938711\ \(0\)\
\-\ suffered\\:\\ 0\\.036577173155177445\ \(0\)\
\-\ metastatic\\:\\ 0\\.036389964224249075\ \(0\)\
\-\ symptoms\\:\\ 0\\.03630326908104008\ \(0\)\
\-\ illustrates\\:\\ 0\\.03577924267778601\ \(0\)\
\-\ tendons\\:\\ 0\\.03577924267778601\ \(0\)\
\-\ picture\\:\\ 0\\.03481917644393219\ \(0\)\
\-\ diplopia\\:\\ 0\\.034694101252056624\ \(0\)\
\-\ importance\\:\\ 0\\.034694101252056624\ \(0\)\
\-\ 84\\:\\ 0\\.034451742340071895\ \(0\)\
\-\ cutaneous\\:\\ 0\\.034451742340071895\ \(0\)\
\-\ this\\:\\ 0\\.0341988720632698\ \(0\)\
\-\ far\\:\\ 0\\.03377994569475849\ \(0\)\
\-\ failed\\:\\ 0\\.033471071045634224\ \(0\)\
\-\ strongly\\:\\ 0\\.033371653714196585\ \(0\)\
\-\ 1999\\:\\ 0\\.033371653714196585\ \(0\)\
\-\ case\\:\\ 0\\.03333380093950796\ \(0\)\
\-\ temp\\:\\ 0\\.03289856600028293\ \(0\)\
\-\ improve\\:\\ 0\\.03221356668808218\ \(0\)\
\-\ support\\:\\ 0\\.03221356668808218\ \(0\)\
\-\ systems\\:\\ 0\\.032054220493876254\ \(0\)\
\-\ decompression\\:\\ 0\\.032054220493876254\ \(0\)\
\-\ differentiated\\:\\ 0\\.03167396925586689\ \(0\)\
\-\ group\\:\\ 0\\.03152856737588142\ \(0\)\
\-\ rhythm\\:\\ 0\\.031457207311682084\ \(0\)\
\-\ seen\\:\\ 0\\.031237307448707848\ \(0\)\
\-\ 64\\:\\ 0\\.031180213425276545\ \(0\)\
\-\ suggested\\:\\ 0\\.031046511622771746\ \(0\)\
\-\ melanoma\\:\\ 0\\.03098079598270538\ \(0\)\
\-\ rr\\:\\ 0\\.030480205660188466\ \(0\)\
\-\ characterized\\:\\ 0\\.030480205660188466\ \(0\)\
\-\ unilateral\\:\\ 0\\.030361512310570986\ \(0\)\
\-\ for\\:\\ 0\\.030165519267953658\ \(0\)\
\-\ poorly\\:\\ 0\\.029964183146198146\ \(0\)\
\-\ asymmetric\\:\\ 0\\.02985547395742971\ \(0\)\
\-\ again\\:\\ 0\\.029592271927208192\ \(0\)\
\-\ vitals\\:\\ 0\\.02929138902686357\ \(0\)\
\-\ 33\\:\\ 0\\.029194457245260562\ \(0\)\
\-\ injection\\:\\ 0\\.028867379851178758\ \(0\)\
\-\ regular\\:\\ 0\\.02864452606289761\ \(0\)\
\-\ hr\\:\\ 0\\.02851480085696909\ \(0\)\
\-\ restricted\\:\\ 0\\.02851480085696909\ \(0\)\
\-\ those\\:\\ 0\\.028387906246256155\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.028102161718661815\ \(0\)\
\-\ idiopathic\\:\\ 0\\.028062463460315247\ \(0\)\
\-\ diffusion\\:\\ 0\\.027944969115395603\ \(0\)\
\-\ herniation\\:\\ 0\\.027906325968130707\ \(0\)\
\-\ 39\\:\\ 0\\.02756962777406132\ \(0\)\
\-\ review\\:\\ 0\\.027320596422005537\ \(0\)\
\-\ additionally\\:\\ 0\\.027320596422005537\ \(0\)\
\-\ total\\:\\ 0\\.027182938580802375\ \(0\)\
\-\ room\\:\\ 0\\.027149027276172365\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.02711531255991989\ \(0\)\
\-\ suggestive\\:\\ 0\\.027015325473667567\ \(0\)\
\-\ bp\\:\\ 0\\.02691702839115301\ \(0\)\
\-\ eye\\:\\ 0\\.026539656757507583\ \(0\)\
\-\ references\\:\\ 0\\.026449019511084287\ \(0\)\
\-\ pathology\\:\\ 0\\.026043776961125947\ \(0\)\
\-\ 16\\:\\ 0\\.025851275199054936\ \(0\)\
\-\ reports\\:\\ 0\\.025797425071115352\ \(0\)\
\-\ extremities\\:\\ 0\\.025211535043408857\ \(0\)\
\-\ 18\\:\\ 0\\.025139288496124776\ \(0\)\
\-\ rate\\:\\ 0\\.025139288496124776\ \(0\)\
\-\ marked\\:\\ 0\\.025091617964746106\ \(0\)\
\-\ causes\\:\\ 0\\.025067928431925433\ \(0\)\
\-\ at\\:\\ 0\\.025061447312949865\ \(0\)\
\-\ rare\\:\\ 0\\.02504433500295033\ \(0\)\
\-\ pattern\\:\\ 0\\.02476843636556238\ \(0\)\
\-\ confirmed\\:\\ 0\\.024462272400367965\ \(0\)\
\-\ greater\\:\\ 0\\.02444100812707627\ \(0\)\
\-\ tumors\\:\\ 0\\.024398711415071366\ \(0\)\
\-\ breast\\:\\ 0\\.024090926780431815\ \(0\)\
\-\ obtained\\:\\ 0\\.02346619507767306\ \(0\)\
\-\ typically\\:\\ 0\\.023289410272901358\ \(0\)\
\-\ biopsy\\:\\ 0\\.02325468914131659\ \(0\)\
\-\ status\\:\\ 0\\.023151752431698196\ \(0\)\
\-\ heart\\:\\ 0\\.023067342063621328\ \(0\)\
\-\ does\\:\\ 0\\.022934783110941624\ \(0\)\
\-\ presentation\\:\\ 0\\.022837309785723334\ \(0\)\
\-\ 12\\:\\ 0\\.022678399017884272\ \(0\)\
\-\ enlarged\\:\\ 0\\.022616030889173994\ \(0\)\
\-\ followed\\:\\ 0\\.022402863540931857\ \(0\)\
\-\ three\\:\\ 0\\.022269841349560313\ \(0\)\
\-\ unremarkable\\:\\ 0\\.022240689547839716\ \(0\)\
\-\ back\\:\\ 0\\.02212552197721244\ \(0\)\
\-\ study\\:\\ 0\\.02212552197721244\ \(0\)\
\-\ radiation\\:\\ 0\\.02198469736638777\ \(0\)\
\-\ several\\:\\ 0\\.021766238922011176\ \(0\)\
\-\ revealed\\:\\ 0\\.021752853939655967\ \(0\)\
\-\ past\\:\\ 0\\.021594591867415386\ \(0\)\
\-\ mr\\:\\ 0\\.021465919090810855\ \(0\)\
\-\ approximately\\:\\ 0\\.021168245305615094\ \(0\)\
\-\ medical\\:\\ 0\\.021084218238436966\ \(0\)\
\-\ severe\\:\\ 0\\.0210013879352452\ \(0\)\
\-\ usually\\:\\ 0\\.020885068612506785\ \(0\)\
\-\ only\\:\\ 0\\.020726033680163247\ \(0\)\
\-\ decreased\\:\\ 0\\.020549450179358827\ \(0\)\
\-\ primary\\:\\ 0\\.020399218926236213\ \(0\)\
\-\ loss\\:\\ 0\\.020211597098463364\ \(0\)\
\-\ when\\:\\ 0\\.020039789420453463\ \(0\)\
\-\ on\\:\\ 0\\.02003900866871579\ \(0\)\
\-\ edema\\:\\ 0\\.019786466161319537\ \(0\)\
\-\ all\\:\\ 0\\.01974845444256253\ \(0\)\
\-\ however\\:\\ 0\\.019635887594236463\ \(0\)\
\-\ with\\:\\ 0\\.019488404370401197\ \(0\)\
\-\ presented\\:\\ 0\\.019345944825534395\ \(0\)\
\-\ months\\:\\ 0\\.019310697613001793\ \(0\)\
\-\ significant\\:\\ 0\\.0191546764816433\ \(0\)\
\-\ enhancement\\:\\ 0\\.01909511428456995\ \(0\)\
\-\ therapy\\:\\ 0\\.01906135063521805\ \(0\)\
\-\ one\\:\\ 0\\.018994405754844033\ \(0\)\
\-\ common\\:\\ 0\\.018814184306331173\ \(0\)\
\-\ than\\:\\ 0\\.018806123636619154\ \(0\)\
\-\ both\\:\\ 0\\.018500166215765206\ \(0\)\
\-\ more\\:\\ 0\\.018216777661430247\ \(0\)\
\-\ bone\\:\\ 0\\.018101467370713983\ \(0\)\
\-\ post\\:\\ 0\\.018051729247319622\ \(0\)\
\-\ noted\\:\\ 0\\.017589485458275413\ \(0\)\
\-\ man\\:\\ 0\\.017563405718311206\ \(0\)\
\-\ demonstrate\\:\\ 0\\.017246909117779867\ \(0\)\
\-\ diagnosis\\:\\ 0\\.017197830579551033\ \(0\)\
\-\ were\\:\\ 0\\.017100898797948023\ \(0\)\
\-\ lower\\:\\ 0\\.01695260488234933\ \(0\)\
\-\ exam\\:\\ 0\\.016700453095123125\ \(0\)\
\-\ but\\:\\ 0\\.016405228340980505\ \(0\)\
\-\ findings\\:\\ 0\\.01637333188662504\ \(0\)\
\-\ images\\:\\ 0\\.015345776202039849\ \(0\)\
\-\ which\\:\\ 0\\.015085130391052866\ \(0\)\
\-\ that\\:\\ 0\\.014396827869232416\ \(0\)\
\-\ from\\:\\ 0\\.013175815163910145\ \(0\)\
\-\ an\\:\\ 0\\.01268611612902455\ \(0\)\
\-\ history\\:\\ 0\\.012674877918249845\ \(0\)\
\-\ ct\\:\\ 0\\.012630140987912571\ \(0\)\
